Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5

(NASDAQ:ARCT) Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children

What are the regulatory timelines and potential risks for FDA approval of the supplemental NDA, and how could this impact the stock volatility? What competitive pressures or alternative treatments exist for pediatric plaque psoriasis, and how could they influence market share for ZORYVE®? How might the expanded pediatric indication for ZORYVE® affect Arcutis' revenue forecasts and earnings guidance?
Symbol: ARCT
Regulatory
10 days ago
Read more globenewswire

Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results

(NASDAQ:ARTL) SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathw...

How does ART27.13's market opportunity and competitive landscape compare to other pipeline assets in the cancer anorexia‑cachexia space? What are the potential near‑term price catalysts from the upcoming full Phase 2 data release and possible partnership announcements? How likely is Artelo Biosciences to secure a development partner for ART27.13 and what terms might be involved?
Symbol: ARTL
Clinical trials
10 days ago
Read more globenewswire

Share buyback program completed

(DEME) DEME Group NV announces that the share buyback program, which commenced on April 22, 2025, was completed on September 1, 2025.

What does the completion of the buyback indicate about DEME's cash position and future capital allocation plans? How does the size and timing of this buyback compare to recent buybacks by peers in the maritime infrastructure sector? What effect will the completed buyback have on DEME's earnings per share and valuation metrics?
Symbol: DEME
Buybacks
10 days ago
Read more globenewswire

Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy

(NASDAQ:GILD) FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences (Nasdaq: GILD) today celebrates the groundbreaking of its new Pharmaceutical Development and Manufacturing (PDM) Technical Develo...

Will the expanded manufacturing capabilities accelerate product launches in virology, oncology, and inflammation, potentially prompting a re‑rating of Gilead's valuation multiples? What timeline and capacity milestones are expected for the new Technical Development Center, and how might they influence Gilead's competitive position in biologics versus peers such as Amgen and Roche? How will the $32 billion investment in the new manufacturing hub affect Gilead's earnings guidance and cash flow?
Symbol: GILD
Manufacturing
10 days ago
Read more businesswire

Bybit and FXStreet TradFi Report Deciphers Latest Gold, Silver, and USD Dynamics

(XAU) DUBAI, UAE, Sept. 3, 2025 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume, has released a new Bybit x FXStreet TradFi Report as rate cut speculatio...

How does the Bybit x FXStreet TradFi Report compare to other institutional gold/silver outlooks, and could its findings impact market sentiment or liquidity on major exchanges? What are the implications of the rate‑cut speculation highlighted in the report for the USD index, and how could that affect currency‑hedged commodity strategies? How might the reported gold price record of $3,508 influence short‑term positioning in XAU/USD futures and related ETFs?
Symbol: XAU
Commodities
10 days ago
Read more prnewswire